Tesamorelin Dosage: How Clinics Approach Treatment
Curious how clinics approach Tesamorelin dosing? This plain-English guide covers standard protocols, what to expect, and why physician oversight matters.
What Is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It works by stimulating the pituitary gland to produce and release growth hormone naturally, rather than introducing exogenous growth hormone directly. The FDA approved it under the brand name Egrifta specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy — a recognized side effect of antiretroviral therapy.
Outside that narrow FDA indication, some licensed clinics prescribe compounded tesamorelin off-label for purposes such as body composition improvement, metabolic support, and age-related hormone decline. Compounded versions are not FDA-approved drug products, and their use beyond the labeled indication should only happen under the direct supervision of a qualified physician.
Why Dosage Isn't One-Size-Fits-All
Tesamorelin dosage decisions depend on a patient's baseline labs, health history, body composition goals, and how well they tolerate the peptide over time. No two patients are identical. A clinic's job is to match the protocol to the individual — not hand out a generic number from a blog post.
That said, understanding the general framework clinics use helps patients ask better questions and set realistic expectations before their first consultation.
The FDA-Approved Reference Point
The FDA-approved dosage for tesamorelin in HIV-associated lipodystrophy is 2 mg injected subcutaneously once daily. This figure comes directly from the clinical trials that led to Egrifta's approval and serves as the primary reference point for prescribing physicians. You can review the FDA's prescribing documentation at fda.gov.
Clinics treating patients off-label often use this approved dose as a starting benchmark, then adjust based on individual response and tolerance.
How Clinics Structure a Starting Protocol
When a patient comes in seeking tesamorelin therapy, most clinics follow a structured intake process before writing any prescription:
- Baseline labs — IGF-1 levels, fasting glucose, HbA1c, and a general metabolic panel are typically ordered. Tesamorelin raises IGF-1, so a pre-treatment baseline is essential for monitoring.
- Medical history review — Active malignancy, pituitary disorders, pregnancy, and certain hypersensitivity conditions are standard contraindications.
- Body composition assessment — DEXA scans or similar tools help establish a clear before-and-after comparison.
After intake, many clinics begin patients at or near the 2 mg/day reference dose, administered subcutaneously, often in the evening to align with the body's natural growth hormone pulse cycle. Some physicians choose a lower starting dose to gauge tolerability before moving to a full protocol.
Monitoring and Dose Adjustments
Tesamorelin therapy isn't static. Responsible clinics schedule follow-up labs — typically at 4 to 12 weeks into treatment — to check IGF-1 levels, blood glucose trends, and any emerging side effects. Why blood glucose? Growth hormone activity can influence insulin sensitivity, making glucose monitoring a standard safety measure.
Common reasons a physician might adjust dosage:
- IGF-1 climbing too high — Elevated IGF-1 above age-appropriate ranges is a signal to reduce frequency or dose.
- Blood glucose changes — Particularly relevant for patients who are pre-diabetic or have metabolic risk factors.
- Fluid retention or joint discomfort — Known potential side effects of elevated growth hormone activity; may prompt a dosage reduction.
- Insufficient response — If labs and body composition show no meaningful change after several weeks, a physician may reassess the entire protocol.
NIH's research database contains published clinical data on tesamorelin's effects on IGF-1 and metabolic markers, which many clinic physicians reference when building monitoring schedules.
Cycle Length: How Long Do Clinics Prescribe It?
The FDA-approved trials ran for 26 weeks, with some extended to 52 weeks. Off-label clinic protocols vary. Some practitioners prefer 3- to 6-month cycles followed by a break, primarily to avoid prolonged IGF-1 elevation and to allow the pituitary to maintain its own rhythm. Others support longer continuous use under close monitoring.
There is no universally agreed-upon off-label cycle standard — which is exactly why ongoing physician oversight matters more than any fixed timeline.
Tesamorelin vs. Other GHRH Peptides
Patients researching tesamorelin often compare it to related peptides like sermorelin and CJC-1295, which also act on the GHRH pathway. The key practical differences that influence how clinics dose them:
- Half-life — Tesamorelin has a longer half-life than sermorelin, which affects injection frequency.
- Specificity — Tesamorelin's structure closely mirrors native GHRH(1-44), giving it a well-characterized clinical profile backed by FDA trial data.
- Combination protocols — Some clinics pair tesamorelin or CJC-1295 with a GHRP like ipamorelin to amplify the growth hormone pulse. Dosing in combination protocols requires particularly careful calibration.
Questions to Ask Your Clinic
Before starting any tesamorelin protocol, patients should feel comfortable asking:
- What labs will you run before and during treatment?
- How will you monitor my IGF-1 levels?
- What side effects should I watch for and report?
- Is this compounded tesamorelin, and how is it sourced?
- What does discontinuation look like if I need to stop?
A clinic that welcomes these questions and answers them clearly is one worth trusting.
The Bottom Line
Tesamorelin dosage is not something to self-determine based on forum posts or generic guides. The FDA-approved 2 mg/day reference dose provides a clinical anchor, but real-world protocols are built around individual lab values, health status, and ongoing monitoring. Whether you're exploring tesamorelin for lipodystrophy management or discussing off-label options with a physician, the path forward runs through a licensed provider — not around one.
This article is for informational purposes only and does not constitute medical advice. Consult a licensed physician before starting any peptide therapy.